{"groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"FG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"FG001","title":"Dacarbazine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"45"}],"type":"Randomized but Not Treated"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"257"},{"groupId":"FG001","numSubjects":"218"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal of Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"6"}],"type":"Refuse Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"43"}],"type":"Reason Not Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"337"},{"groupId":"FG001","numSubjects":"338"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"336"},{"groupId":"FG001","numSubjects":"293"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"337"},{"groupId":"FG001","numSubjects":"338"}],"type":"NOT COMPLETED"}],"title":"Vemurafenib and Dacarbazine"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"65"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal of Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"10"}],"type":"Reason Not Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"Participants who crossed over from dacarbazine to vemurafenib treatment.","groupId":"FG001","numSubjects":"84"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"84"}],"type":"NOT COMPLETED"}],"title":"Crossover: Dacarbazine to Vemurafenib"}],"preAssignmentDetails":"675 participants were randomized, 337 to vemurafenib and 338 to dacarbazine. One participant randomized to dacarbazine was treated in error with vemurafenib throughout the study and is included in the Vemurafenib arm in the table below and for exposure and safety analyses and is included in the dacarbazine arm for efficacy analyses."}